<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03212313</url>
  </required_header>
  <id_info>
    <org_study_id>TOZ-CL11</org_study_id>
    <nct_id>NCT03212313</nct_id>
  </id_info>
  <brief_title>Study to Investigate the Influence of Hepatic Insufficiency on the Pharmacokinetics of Tozadenant</brief_title>
  <official_title>A Two-Part, Open-Label, Single-Dose Study to Investigate the Influence of Hepatic Insufficiency on the Pharmacokinetics of Tozadenant</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Biotie Therapies Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Acorda Therapeutics</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Biotie Therapies Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a two-part, open label, single-dose study that will evaluate the PK of tozadenant in&#xD;
      subjects with different degrees of hepatic impairment to the PK of a single-dose of&#xD;
      tozadenant in healthy subjects.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    New Safety Information&#xD;
  </why_stopped>
  <start_date type="Actual">June 30, 2017</start_date>
  <completion_date type="Actual">December 31, 2017</completion_date>
  <primary_completion_date type="Actual">December 31, 2017</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To evaluate the pharmacokinetics (PK) [area under the time-concentration curve] of a single-dose of tozadenant in subjects with hepatic impairment to healthy subjects.</measure>
    <time_frame>up to 12 days</time_frame>
    <description>To evaluate the pharmacokinetics (PK) [area under the time-concentration curve] of a single-dose of tozadenant in subjects with hepatic impairment compared to the PK of a single-dose of tozadenant in healthy subjects.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Subjects with hepatic impairment will be evaluated for safety assessments (adverse events and treatment-related adverse events) by physical examinations.</measure>
    <time_frame>up to 12 days</time_frame>
    <description>To evaluate the safety and tolerability of a single-dose of tozadenant in subjects with hepatic impairment by physical examinations, vital sign measurements and Columbia-Suicide Severity Rating Scale (C-SSRS) questionnaire.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">20</enrollment>
  <condition>Hepatic Impairment</condition>
  <arm_group>
    <arm_group_label>Healthy Subjects</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Study dose of 120 mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Mild Hepatic Impairment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Study dose of 120 mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Moderate Hepatic Impairment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Study dose of 120 mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Severe Hepatic Impairment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Up to a maximum study dose of 120 mg</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tozadenant</intervention_name>
    <description>Two 60 mg tablets for a total single study dose of 120 mg</description>
    <arm_group_label>Healthy Subjects</arm_group_label>
    <arm_group_label>Mild Hepatic Impairment</arm_group_label>
    <arm_group_label>Moderate Hepatic Impairment</arm_group_label>
    <arm_group_label>Severe Hepatic Impairment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        All subjects must fulfill the following to participate:&#xD;
&#xD;
          -  Subject has given his/her written informed consent on an IEC or IRB approved consent&#xD;
             form.&#xD;
&#xD;
          -  Subject understands the study procedures in the informed consent form (ICF), and is&#xD;
             willing and able to comply with the protocol.&#xD;
&#xD;
          -  Be either male or female 18 years old&#xD;
&#xD;
          -  Have a BMI ≥ 18.5 and ≤ 40.0 kg/m2 at screening&#xD;
&#xD;
          -  Is a continuous non-smoker or a smoker who will consume up to 10 cigarettes/day&#xD;
&#xD;
          -  Child bearing females should be sexually inactive (abstinent) prior to dosing&#xD;
&#xD;
          -  Females subjects of non childbearing potential must have undergone one of the&#xD;
             following sterilization or be postmenopausal&#xD;
&#xD;
        Subjects with mild, moderate, or severe hepatic impairment must:&#xD;
&#xD;
          -  Have a medical history consistent with a diagnosis of hepatic impairment.&#xD;
&#xD;
          -  Have a diagnosis of chronic (&gt; 6 months), stable hepatic insufficiency&#xD;
&#xD;
        Healthy subjects must be:&#xD;
&#xD;
          -  Medically healthy with no significant medical history&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Subjects must not be enrolled in the study if they:&#xD;
&#xD;
          -  Previously participated in any study with tozadenant&#xD;
&#xD;
          -  Has orthostatic hypotension, history or symptoms of cardiovascular disease, or&#xD;
             hypertensive crisis.&#xD;
&#xD;
          -  Currently participating in or has participated in another study and received drug&#xD;
             (active or placebo)&#xD;
&#xD;
          -  Have a known diagnosis of malignant melanoma&#xD;
&#xD;
          -  Have a current episode of major depression&#xD;
&#xD;
          -  Has a recent history of suicide attempt&#xD;
&#xD;
          -  Has any other condition or clinically significant abnormal findings on the physical or&#xD;
             neurological examination, psychiatric and medical history&#xD;
&#xD;
          -  Had surgery or any medical condition within 6 months&#xD;
&#xD;
          -  Unable to refrain from or anticipates the use of any drugs, vitamins, natural or&#xD;
             herbal supplements&#xD;
&#xD;
          -  Subject is currently lactating or pregnant or planning to become pregnant.&#xD;
&#xD;
          -  Recent donation of blood, plasma or significant blood loss&#xD;
&#xD;
          -  Has positive test for ethanol or drugs of abuse or a history of chronic alcohol or&#xD;
             drug abuse&#xD;
&#xD;
          -  Clinically significant medical history&#xD;
&#xD;
          -  Positive results hepatitis B surface antigen (HBsAg) or hepatitis C virus (HCV) for&#xD;
             Healthy Volunteers only.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Richard Preston, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Miami</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Miami</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Orlando Clinical Research Center</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32809-3017</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2017</verification_date>
  <study_first_submitted>June 30, 2017</study_first_submitted>
  <study_first_submitted_qc>July 6, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">July 11, 2017</study_first_posted>
  <last_update_submitted>January 2, 2018</last_update_submitted>
  <last_update_submitted_qc>January 2, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 4, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Adults</keyword>
  <keyword>Liver Disease</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatic Insufficiency</mesh_term>
    <mesh_term>Liver Failure</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

